Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (DE:41X)
FRANKFURT:41X
Holding DE:41X?
Track your performance easily
41X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.45 - €9.12
Previous Close€4.56
Volume0.00
Average Volume (3M)2.67K
Market Cap
€1.02B
Enterprise Value€942.39M
Total Cash (Recent Filing)$190.40M
Total Debt (Recent Filing)$104.49M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 05, 2025EPS Estimate
<€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding236,854,270
10 Day Avg. Volume1,835
30 Day Avg. Volume2,665
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.34
Price to Sales (P/S)4.32
Price to Cash Flow (P/CF)542.50
P/FCF Ratio746.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.74
Enterprise Value/Gross Profit8.84
Enterprise Value/Ebitda-17.18
Forecast
1Y Price Target
€9.41Price Target Upside121.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Ardelyx News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceXPHOZAH's net sales revenue in the U.S. was significantly higher than estimated, indicating strong market performance.
Growth PotentialXphozah continues to show robust demand with ~39% Q/Q growth, which might not be fully appreciated by investors at current levels.
Legal And Legislative OpportunitiesThere is strong bipartisan support for the Kidney PATIENT Act which would delay the inclusion of oral ESRD drugs in the bundle for at least two years.
Bears Say
Investor SentimentAnalyst believes there is significant uncertainty around Medicare patient access for XPHOZAH, creating an overhang on investor sentiment and the stock.
Legal And Corporate RiskThe analyst downgrades ARDX shares to Neutral due to the recent court decision and increased corporate risk and uncertainty.
Reimbursement UncertaintyUncertainty surrounds XPHOZAH's reimbursement status for Medicare patients, which affects a large portion of its addressable market.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.39% Insiders
20.21% Mutual Funds
3.95% Other Institutional Investors
59.57% Public Companies and
Individual Investors
41X FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was €3.45 and its highest was €9.12 in the past 12 months.
What is Ardelyx’s market cap?
Currently, no data Available
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 05, 2025 which is in 111 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 31, 2024. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.046 by €0.046.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is <€0.01.
How many shares outstanding does Ardelyx have?
Ardelyx has 236,854,260 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of €0 in its last earnings report, beating expectations of -€0.046. Following the earnings report the stock price went up 3.279%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 11M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.41 (121.42% Upside)
€9.41 (121.42% Upside)
Blogger Sentiment
Bullish
DE:41X Sentiment 96%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $847.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.68%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
27.12%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
41X Earnings Call
Q3 2024
0:00 / 0:00
---
41X Stock 12 Month Forecast
Average Price Target
€9.41
▲(121.42% Upside)
Technical Analysis
Ardelyx
―
Karyopharm Therapeutics
―
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering 41X
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+49.19%
reiterated a buy rating 14 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +49.19% per trade.
---